Product Description
BTK (Bruton's tyrosine kinase) is a member of the non-receptor tyrosine kinase family belonging to the Tec kinase subfamily, which plays a pivotal role in B-cell development, differentiation, proliferation, and survival. BTK is activated downstream of the B-cell receptor (BCR) and various cytokine receptors, leading to phosphorylation of downstream effectors such as PLCγ2, NF-κB, and MAPKs. Beyond its essential physiological functions in the immune system, dysregulation of BTK signaling—including activating mutations, overexpression, and aberrant activation—is closely associated with B-cell malignancies (such as chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström's macroglobulinemia), as well as autoimmune diseases and inflammatory disorders. These features have established BTK as a highly validated target for cancer therapy and drug discovery.
Screeningbio’s BTK Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying BTK kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: BTK catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the BTK kinase.
Data